ArticleInternational journal of women's health2025
A Retrospective Study of Clinicopathological Features and Survival Outcomes in 305 Surgically Treated Patients with Stage IB-IIA Cervical Squamous Cell Carcinoma.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinicopathological characteristics and survival outcomes of 305 surgically treated patients with stage IB-IIA cervical squamous cell carcinoma (CSCC). Methods: Clinical data of 305 CSCC patients treated at our hospital from March 2015 to December 2019 were retrospectively analyzed. Clinicopathological features were summarized, prognostic factors identified, and survival outcomes assessed using Kaplan-Meier and Cox regression analyses. Results: The most common symptoms were irregular bleeding (49.8%) and contact vaginal bleeding (35.7%). Tumors <4 cm accounted for 75.1%, and International Federation of Gynecology and Obstetrics (FIGO) stage IIA was more frequent than stage IB (52.8% vs 47.2%). Deep stromal invasion (≥1/2) and lymph node metastasis were observed in 75.7% and 19.3% of patients, respectively. Ovarian preservation occurred in 12.8% of cases. Postoperative adjuvant therapy was given in 79.3% of patients, with 41.3% receiving concurrent chemoradiotherapy. Lower apparent diffusion coefficient (ADC) values were significantly associated with higher FIGO stage, deeper invasion, lymph node metastasis, and more intensive adjuvant therapy (P<0.05). The 3-year overall survival (OS) and disease-free survival (DFS) rates were 88.5% and 84.6%, respectively. Cox analysis identified FIGO stage, lymph node metastasis, depth of invasion, and adjuvant therapy as independent prognostic factors (P<0.05). Kaplan-Meier analysis showed significantly lower OS in patients with FIGO stage IIA, deep invasion, lymph node metastasis, and no or single-modality adjuvant therapy. Conclusion: The pathological features of patients with CSCC are closely associated with ADC values derived from diffusion-weighted imaging (DWI). Vaginal bleeding, depth of invasion, FIGO stage, postoperative treatment, and lymph node metastasis are key prognostic factors. Patients with stage IIa, lymph node metastasis, no adjuvant therapy, or invasion depth ≥1/2 have a poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.